Harvard Medical School, Boston, MA, USA.
Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
Breast Cancer Res Treat. 2024 Oct;207(3):587-597. doi: 10.1007/s10549-024-07400-z. Epub 2024 Jun 10.
We evaluated the incidence, timing, and risk factors for second primary non-breast cancers (SPNBC) among young breast cancer (BC) survivors.
This study included participants of the Young Women's BC Study (YWS) who were diagnosed with stage 0-III BC between 2006 and 2016 and age 40 or younger at diagnosis (N = 1,230). Patient characteristics, treatment information, and clinical events were collected via serial surveys. Tumor and treatment data were obtained from medical record review. Five- and 10-year risks of SPNBCs were estimated via the cumulative incidence function, considering death, metastasis, or second primary BC as competing events. Fine and Gray subdistribution hazard models estimated subdistribution hazard ratios (sHRs) and 95% confidence intervals (CI) for SPNBC risk based on risk factors including demographics, germline genetics, primary BC characteristics, and treatments.
Among 1,230 women, over a median follow-up of 10.1 years, 47 patients (4%) developed an SPNBC. Types of malignancy included melanoma (n = 10), thyroid (n = 10), ovarian (n = 4), sarcoma (n = 4), uterine (n = 3), rectal (n = 3), bladder (n = 2), cervical (n = 2), head/neck (n = 2), lung (n = 2), lymphoma (n = 2), pancreatic (n = 2), and renal (n = 1). Five and 10-year cumulative incidence were 1.4% and 3.2%, respectively. Median time between primary BC and SPNBC was 7.3 years. No patient factors, primary tumor characteristics, or treatments were statistically significantly associated with SPNBC in univariable or multivariable models.
In this population, five-year cumulative incidence was higher than that reported among healthy women under 50 years of age, highlighting the importance of long-term surveillance for new non-breast cancers in young adult BC survivors.
我们评估了年轻乳腺癌(BC)幸存者中第二原发非乳腺癌(SPNBC)的发生率、时间和风险因素。
本研究纳入了 2006 年至 2016 年间诊断为 0-III 期 BC 且诊断时年龄在 40 岁或以下的年轻女性 BC 研究(YWS)的参与者(N=1230)。通过连续调查收集患者特征、治疗信息和临床事件。肿瘤和治疗数据通过病历回顾获得。通过累积发生率函数估计 SPNBC 的 5 年和 10 年风险,将死亡、转移或第二原发 BC 作为竞争事件。精细和灰色亚分布风险模型根据包括人口统计学、种系遗传学、原发性 BC 特征和治疗在内的风险因素,估计 SPNBC 风险的亚分布风险比(sHR)和 95%置信区间(CI)。
在 1230 名女性中,中位随访时间为 10.1 年,有 47 名患者(4%)发生 SPNBC。恶性肿瘤类型包括黑色素瘤(n=10)、甲状腺(n=10)、卵巢(n=4)、肉瘤(n=4)、子宫(n=3)、直肠(n=3)、膀胱(n=2)、宫颈(n=2)、头颈部(n=2)、肺(n=2)、淋巴瘤(n=2)、胰腺(n=2)和肾(n=1)。5 年和 10 年累积发生率分别为 1.4%和 3.2%。原发性 BC 和 SPNBC 之间的中位时间为 7.3 年。单变量或多变量模型均未显示患者因素、原发性肿瘤特征或治疗与 SPNBC 有统计学显著关联。
在本研究人群中,5 年累积发生率高于报告的 50 岁以下健康女性,突出了对年轻成年 BC 幸存者新发非乳腺癌进行长期监测的重要性。